Biopharma's Migraine Phase 3 Trial Results 'Robust,' 'Impressive'
Source: Streetwise Reports  (1/3/20)
These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. More >

Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder
Source: Streetwise Reports  (1/3/20)
The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report. More >

Biopharma Releases Topline Results from Psoriasis Trial
Source: Streetwise Reports  (1/3/20)
The company, however, will continue to advance the same therapeutic in two other diseases. More >

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise
Source: Streetwise Reports  (1/3/20)
Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity financing from BeiGene and two other investment groups. More >

Pulmatrix's Licensing Deal with the JNJ Lung Cancer Initiative Sends Shares Up 100%
Source: Streetwise Reports  (1/2/20)
Pulmatrix's shares opened 90% higher today after the firm reported that it has signed a kinase inhibitor licensing agreement with the Lung Cancer Initiative at Johnson & Johnson. More >

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment
Source: Streetwise Reports  (12/30/19)
Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). More >

Iterum Therapeutics Shares Double After Completing Enrollment in Phase 3 Antibiotic Trial
Source: Streetwise Reports  (12/27/19)
Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results in Q1/20. More >

Biopharma Continues 'Positive Push Forward in Breast Cancer'
Source: Streetwise Reports  (12/27/19)
The latest clinical trial results and next step are reviewed in an H.C. Wainwright & Co. report. More >

Coverage Initiated on Immunotherapies Developer with 'Catalyst Rich 2020'
Source: Streetwise Reports  (12/23/19)
The key business and investment points are presented in a ROTH Capital Partners report. More >

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug
Source: Streetwise Reports  (12/23/19)
Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. More >

NewLink Genetics Shares Shoot Higher after FDA Ebola Vaccine Approval
Source: Streetwise Reports  (12/20/19)
Shares of NewLink Genetics got a boost today after the firm reported that the FDA approved its ERVEBO V920 vaccine used in the treatment of Zaire Ebola virus. The company's shares set a new 52-week high price in mid-morning trading. More >

Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax
Source: Streetwise Reports  (12/19/19)
Shares of Paratek Pharmaceuticals traded 40% higher today after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax. More >

Agreement Sets Stage to Secure Chinese Approval of Non-Antibiotic Livestock Feed Supplement
Source: Streetwise Reports  (12/18/19)
The requirements include, among others, trials of the company's livestock feed additive. More >

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease
Source: Streetwise Reports  (12/18/19)
Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 million over three years. More >

Biopharma to Test Immunity Activator in Advanced Solid Cancers
Source: Streetwise Reports  (12/17/19)
The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. More >

Biopharma 'Keeps Executing and Securing Milestones'
Source: Streetwise Reports  (12/17/19)
The company's latest achievement and partnership potential are addressed in a ROTH Capital Partners report. More >

Feed Additive Developer Signs MOU with Philippine Distributor
Source: Streetwise Reports  (12/17/19)
This is the first step toward a binding, definitive agreement between the two companies. More >

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome
Source: Streetwise Reports  (12/16/19)
Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application filing in H2/20. More >

Animal Health Product Developer Lands First Sale in Malaysia
Source: Streetwise Reports  (12/15/19)
The maiden order comes on the heels of the country approving use of the product there. More >

Sarepta Shares Get a 35% Boost from FDA Approval of 2nd DMD Drug
Source: Streetwise Reports  (12/13/19)
Sarepta Therapeutics shares traded 35% higher after the firm reported that the FDA approved its second RNA exon-skipping treatment drug VYONDYS 53 injection for the treatment of Duchenne's Muscular Dystrophy in patients amenable to skipping Exon 53. More >

Assertio Therapeutics' Shares Jump 50% on Sale of Shingles Pain Drug to Alvogen
Source: Streetwise Reports  (12/12/19)
Assertio Therapeutics' shares rose 50% today after the firm reported that it has agreed to sell all rights to its Gralise drug used in the treatment of pain from shingles to Alvogen for $127.5 million. The transaction is expected to close in January 2020. More >

Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research
Source: Streetwise Reports  (12/11/19)
Proteostasis Therapeutics' shares traded higher today after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-2020, and potential for a Marketing Authorization Application in 2021. More >

Avid Bioservices' Shares Rise on Q2/20 Earnings and Confirmed Outlook
Source: Streetwise Reports  (12/10/19)
Shares of Avid Bioservices traded higher today, reaching a new 52-week high, after the firm reported Q2/20 earnings and reaffirmed its revenue guidance for Full-Year 2020. More >

Analyst Believes Biopharma's Alzheimer's Treatment Could Be Superior to Biogen's
Source: Streetwise Reports  (12/10/19)
How this company's Alzheimer's therapeutic compares to an advanced-stage competitor is outlined in a Dawson James Securities note. More >

ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck
Source: Streetwise Reports  (12/9/19)
ArQule Inc. shares traded more than 100% higher today after the company entered into definitive agreement to be acquired by a Merck subsidiary company for $20 per share. The deal is valued at $2.7 billion and is expected to close in the early part of Q1/20. More >